Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Abstract: The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness–implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas

Safety and Nanotoxicity Aspects of Nanomedicines for Brain-Targeted Drug Delivery

Nanotechnology for brain drug delivery comprises the promise for future possibilities of successful treatment in several central nervous system pathologies currently deficient in curative treatments, such as neurodegenerative disorders and malignant glioblastoma. Nevertheless, the neurotoxic effects exerted by several types of nanomaterials are the same as those involved in the pathology of neurodegeneration; thus it is important to have a deep knowledge of these mechanisms so that a proper approach can be taken into consideration. On the other hand, cancer cells usually respond differently to normal cells, being this characteristic a potential advantage for brain cancer therapy. In this chapter we analyze the mechanisms behind neurotoxic effects, from a multidisciplinary perspective, aiming to highlight the disadvantages of nanomaterials for the development of brain-targeted nanocarriers.Fil: Catalan Figueroa, Johanna Francesca. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Farmacología Experimental de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Instituto de Farmacología Experimental de Córdoba; Argentina. Universidad de Chile; Chile. Centro de Estudios Avanzados de Enfermedades Crónicas; ChileFil: Morales Montecinos, Javier Octavio. Universidad de Chile; Chile. Centro de Estudios Avanzados de Enfermedades Crónicas; Chile. Luleå University of Technology; Sueci